CS23546 is a highly potent small-molecule PD-L1 inhibitor exclusively discovered by the company with global patent protection. It blocks the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway by binding to PD-L1 and inducing its endocytosis. In preclinical studies, CS23546 demonstrated favorable oral absorption and metabolic characteristics of local enrichment in tumor tissues. It exhibited significant antitumor efficacy as a monotherapy in various tumor xenograft models and showed marked synergistic antitumor activity when combined with chemotherapy or other proprietary products such as Chidamide and Chiauranib. With a stable manufacturing process and controllable quality, CS23546 is expected to offer differentiated advantages as a new-generation oral small-molecule immune checkpoint inhibitor in the clinical treatment of various malignant tumors. It also holds potential for application in other immune-related diseases mediated by PD-L1 signaling.

The Phase I clinical study of CS23546 is progressing smoothly. The company is exploring and optimizing dosing regimens based on clinical efficacy responses, and subsequent clinical protocols will be developed according to the MTD dose.